Epidemiology of aplasia cutis congenita: A population-based study in Europe.


Journal

Journal of the European Academy of Dermatology and Venereology : JEADV
ISSN: 1468-3083
Titre abrégé: J Eur Acad Dermatol Venereol
Pays: England
ID NLM: 9216037

Informations de publication

Date de publication:
Mar 2023
Historique:
received: 20 07 2022
accepted: 06 10 2022
pubmed: 28 10 2022
medline: 16 2 2023
entrez: 27 10 2022
Statut: ppublish

Résumé

Aplasia cutis congenita (ACC) is a rare congenital anomaly characterized by localized or widespread absence of skin at birth, mainly affecting the scalp. Most information about ACC exists as individual case reports and medium-sized studies. This study aimed to investigate the epidemiology of ACC, using data from a large European network of population-based registries for congenital anomalies (EUROCAT). Twenty-eight EUROCAT population-based registries in 16 European countries were involved. Poisson regression models were exploited to estimate the overall and live birth prevalence, to test time trends in prevalence between four 5-year periods and to evaluate the impact of the change of coding for ACC from the unspecific ICD9-BPA code to the specific ICD10 code. Proportions of ACC cases associated with other anomalies were reported. Five hundred cases were identified in the period 1998-2017 (prevalence: 5.10 per 100,000 births). Prevalence across 5-year periods did not differ significantly and no significant differences were evident due to the change from ICD9 to ICD10 in ACC coding. Heterogeneity in prevalence was observed across registries. The scalp was the most common site for ACC (96.4%) and associated congenital anomalies were present in 33.8% of cases. Patau and Adams-Oliver syndromes were the most frequent among the associated chromosomal anomalies (88.3%) and the associated genetic syndromes (57.7%), respectively. 16% of cases were associated with limb anomalies and 15.4% with congenital heart defects. A family history of ACC was found in 2% of cases. To our knowledge, this is the only population-based study on ACC. The EUROCAT methodologies provide reliable prevalence estimates and proportions of associated anomalies.

Sections du résumé

BACKGROUND BACKGROUND
Aplasia cutis congenita (ACC) is a rare congenital anomaly characterized by localized or widespread absence of skin at birth, mainly affecting the scalp. Most information about ACC exists as individual case reports and medium-sized studies.
OBJECTIVES OBJECTIVE
This study aimed to investigate the epidemiology of ACC, using data from a large European network of population-based registries for congenital anomalies (EUROCAT).
METHODS METHODS
Twenty-eight EUROCAT population-based registries in 16 European countries were involved. Poisson regression models were exploited to estimate the overall and live birth prevalence, to test time trends in prevalence between four 5-year periods and to evaluate the impact of the change of coding for ACC from the unspecific ICD9-BPA code to the specific ICD10 code. Proportions of ACC cases associated with other anomalies were reported.
RESULTS RESULTS
Five hundred cases were identified in the period 1998-2017 (prevalence: 5.10 per 100,000 births). Prevalence across 5-year periods did not differ significantly and no significant differences were evident due to the change from ICD9 to ICD10 in ACC coding. Heterogeneity in prevalence was observed across registries. The scalp was the most common site for ACC (96.4%) and associated congenital anomalies were present in 33.8% of cases. Patau and Adams-Oliver syndromes were the most frequent among the associated chromosomal anomalies (88.3%) and the associated genetic syndromes (57.7%), respectively. 16% of cases were associated with limb anomalies and 15.4% with congenital heart defects. A family history of ACC was found in 2% of cases.
CONCLUSION CONCLUSIONS
To our knowledge, this is the only population-based study on ACC. The EUROCAT methodologies provide reliable prevalence estimates and proportions of associated anomalies.

Identifiants

pubmed: 36300660
doi: 10.1111/jdv.18690
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

581-589

Subventions

Organisme : Medical Research Council
ID : MR/K02325X/1
Pays : United Kingdom

Informations de copyright

© 2022 European Academy of Dermatology and Venereology.

Références

Bajpai M, Pal K. Aplasia cutis cerebri with partial acrania-total reconstruction in a severe case and review of the literature. J Pediatr Surg. 2003;38:E4.
Orphanet. Aplasia cutis congenita. https://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3198&Disease_Disease_Search_diseaseGroup=1114&Disease_Disease_Search_diseaseType=ORPHA&Disease(s)/group%20of%20diseases=Aplasia-cutis-congenita&title=Aplasia%20cutis%20congenita&search=Disease_Search_Simple; (2019). Accessed 14 March 2022.
Frieden IJ. Aplasia cutis congenita: a clinical review and proposal for classification. J Am Acad Dermatol. 1986;14:646-60.
Mesrati H, Amouri M, Chaaben H, Masmoudi A, Boudaya S, Turki H. Aplasia cutis congenita: report of 22 cases. Int J Dermatol. 2015;54:1370-5.
Sathishkumar D, Ogboli M, Moss C. Classification of aplasia cutis congenita: a 25-year review of cases presenting to a tertiary paediatric dermatology department. Clin Exp Dermatol. 2020;45:994-1002.
Brackenrich J, Brown A. Aplasia Cutis Congenita. In: StatPearls [Internet]. Treasure Island, FL: StatPearls Publishing; 2022.
Chiaverini C, Charlesworth A, Fernandez A, Barbarot S, Bessis D, Bodemer C, et al. Aplasia cutis congenita with dystrophic epidermolysis bullosa: clinical and mutational study. Br J Dermatol. 2014;170(4):901-6.
Hsu CH, Tu WT, Chen PC, Yu-Yun Lee J, Hsu CK, Chiu TM. Novel compound heterozygous ITGB4 mutations underlie lethal junctional epidermolysis bullosa with pyloric atresia and aplasia cutis congenita. J Dermatol. 2022;49(5):e154-6.
Marneros AG. BMS1 is mutated in aplasia cutis congenita. PLoS Genet. 2013;9(6):e1003573.
Drolet B, Prendiville J, Golden J, Enjolras O, Esterly NB. 'Membranous Aplasia Cutis' with hair collars: congenital absence of skin or neuroectodermal defect? Arch Dermatol. 1995;131:1427-31.
Üstüner P, Dilek N, Saral Y, Üstüner I. Coexistence of aplasia cutis congenita, faun tail nevus and fetus papyraceus. J Dermatol Case Rep. 2013;7(3):93-6.
Li H, Zheng J, Luo J, Zeng R, Feng N, Zhu N, et al. Congenital anomalies in children exposed to antithyroid drugs in-utero: a meta-analysis of cohort studies. PLoS ONE. 2015;10(5):e0126610.
Romeo AN, Običan SG. Teratogen update: antithyroid medications. Birth Defects Res. 2020;112:1150-60.
Martínez-Lage JF, Almagro MJ, López Hernández F, Poza M. Aplasia cutis congenita of the scalp. Childs Nerv Syst. 2002;18(11):634-7.
Sharif S, Hay CR, Clayton-Smith J. Aplasia cutis congenita and low molecular weight heparin. BJOG. 2005;112(2):256-8.
Mihçi E, Erişir S, Taçoy S, Lüleci G, Alpsoy E, Oygür N. Aplasia cutis congenita: three cases with three different underlying etiologies. Turk J Pediatr. 2009;51(5):510-4.
Pajaziti L, Rexhepi S, Shatri-Muça Y, Ferizi M. The role of diclofenac on inducing of aplasia cutis congenita: a case report. Cases J. 2009;2:150.
Zhou J, Zheng L, Tao W. Systemic aplasia cutis congenita: a case report and review of the literature. Pathol Res Pract. 2010;206:504-7.
Duan X, Yang G, Yu D, Yu C, Wang B, Guo Y. Aplasia cutis congenita: a case report and literature review. Exp Ther Med. 2015;10:1893-5.
Perry BM, Maughan CB, Crosby MS, Hadenfeld SD. Aplasia cutis congenita type V: a case report and review of the literature. Int J Dermatol. 2017;56:e118-21.
Humphrey SR, Hu X, Adamson K, Schaus A, Jensen JN, Drolet B. A practical approach to the evaluation and treatment of an infant with aplasia cutis congenita. J Perinatol. 2018;38:110-7.
Chessa MA, Filippi F, Patrizi A, Vollono L, Sechi A, D'Ercole M, et al. Aplasia cutis: clinical, dermoscopic findings and management in 45 children. J Eur Acad Dermatol Venereol. 2020;34:e724-6.
Kuemmet TJ, Miller JJ, Michalik D, Lew SM, Maheshwari M, Humphrey SR. Low risk of clinically important central nervous system dysraphism in a cohort study of 69 patients with isolated aplasia cutis congenita of the head. Pediatr Dermatol. 2020;37:455-60.
Schierz IAM, Giuffrè M, Del Vecchio A, Antona V, Corsello G, Piro E. Recognizable neonatal clinical features of aplasia cutis congenita. Ital J Pediatr. 2020;46:25.
Yang M-Y, Ha D-L, Kim H-S, Ko H-C, Kim B-S, Kim M-B. Aplasia cutis congenita in Korea: single center experience and literature review. Pediatr Int. 2020;62:804-9.
EUROCAT Guide 1.4: Instruction for the registration of congenital anomalies. EUROCAT Central Registry. University of Ulster; 2021. https://eu-rd-platform.jrc.ec.europa.eu/eurocat/data-collection/guidelines-for-data-registration_en. Accessed 14 March 2022.
Boyd PA, Haeusler M, Barisic I, Loane M, Garne E, Dolk H. Paper 1: The EUROCAT network-organization and processes. Birth Defects Res A Clin Mol Teratol. 2011;91(Suppl 1):S2-15.
EUROCAT. Members Registries. https://eu-rd-platform.jrc.ec.europa.eu/eurocat/eurocat-members/registries_en. Accessed 14 March 2022.
Kinsner-Ovaskainen A, Lanzoni M, Garne E, Loane M, Morris J, Neville A, et al. A sustainable solution for the activities of the European network for surveillance of congenital anomalies: EUROCAT as part of the EU Platform on Rare Diseases Registration. Eur J Med Genet. 2018;61(9):513-7.
Tucker FD, Morris JK, JRC Management Committee, Neville A, Garne E, Kinsner-Ovaskainen A, et al. EUROCAT: an update on its functions and activities. J Community Genet. 2018;9(4):407-10.
StataCorp. Stata Statistical Software: Release 16. College Station, TX: StataCorp LLC; 2019.
Orphanet Report Series. Prevalence, incidence or reported number of published cases listed in alphabetical order of disease January 2022. https://www.orpha.net/orphacom/cahiers/docs/GB/Prevalence_of_rare_diseases_by_alphabetical_list.pdf.
Browning JC. Aplasia cutis congenita: approach to evaluation and management. Dermatol Ther. 2013;26:439-44.

Auteurs

Alessio Coi (A)

Unit of Epidemiology of Rare Diseases and Congenital Anomalies, Institute of Clinical Physiology, National Research Council, Pisa, Italy.

Ingeborg Barisic (I)

Children's Hospital Zagreb, Centre of Excellence for Reproductive and Regenerative Medicine, Medical School University of Zagreb, Zagreb, Croatia.

Ester Garne (E)

Department of Paediatrics and Adolescent Medicine, Lillebaelt Hospital, University Hospital of Southern Denmark, Kolding, Denmark.

Anna Pierini (A)

Unit of Epidemiology of Rare Diseases and Congenital Anomalies, Institute of Clinical Physiology, National Research Council, Pisa, Italy.
Fondazione Toscana Gabriele Monasterio, Pisa, Italy.

Marie-Claude Addor (MC)

Department of Woman-Mother-Child, University Medical Center CHUV, Lausanne, Switzerland.

Amaia Aizpurua Atxega (A)

Public Health Division of Gipuzkoa, Biodonostia Research Institute, Donostia-San Sebastian, Spain.

Elisa Ballardini (E)

Neonatal Intensive Care Unit, Paediatric Section, IMER Registry (Emilia Romagna Registry of Birth Defects), Department of Medical Sciences, University of Ferrara, Ferrara, Italy.

Paula Braz (P)

Epidemiology Department, National Institute of Health Doutor Ricardo Jorge, Lisbon, Portugal.

Jennifer M Broughan (JM)

National Congenital Anomaly and Rare Disease Registration Service, National Disease Registration Service, NHS Digital, Leeds, UK.

Clara Cavero-Carbonell (C)

Rare Diseases Research Unit, Foundation for the Promotion of Health and Biomedical Research in the Valencian Region, Valencia, Spain.

Hermien E K de Walle (HEK)

Department of Genetics, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.

Elizabeth S Draper (ES)

Department Health Sciences, College of Life Sciences, University of Leicester, Leicester, UK.

Miriam Gatt (M)

Malta Congenital Anomalies Registry, Directorate for Health Information and Research, G'Mangia, Malta.

Martin Häusler (M)

Medical University of Graz, Graz, Austria.

Agnieszka Kinsner-Ovaskainen (A)

European Commission, Joint Research Centre (JRC), Ispra, Italy.

Jennifer J Kurinczuk (JJ)

National Perinatal Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK.

Nathalie Lelong (N)

Université Paris Cité, Inserm, INRAE, Centre for Research in Epidemiology and StatisticS (CRESS), Obstetrical Perinatal and Pediatric Epidemiology Research Team, EPOPé, Paris, France.

Karen Luyt (K)

South West Congenital Anomaly Register, Bristol Medical School, University of Bristol, Bristol, UK.

Lorena Mezzasalma (L)

Unit of Epidemiology of Rare Diseases and Congenital Anomalies, Institute of Clinical Physiology, National Research Council, Pisa, Italy.

Carmel Mullaney (C)

Department of Public Health, HSE South East, Lacken, Kilkenny, Ireland.

Vera Nelen (V)

Provincial Institute of Hygiene, Antwerp, Belgium.

Ljubica Odak (L)

Children's Hospital Zagreb, Centre of Excellence for Reproductive and Regenerative Medicine, Medical School University of Zagreb, Zagreb, Croatia.

Mary T O'Mahony (MT)

Department of Public Health, HSE South (Cork & Kerry), Cork, Ireland.

Isabelle Perthus (I)

Auvergne Registry of Congenital Anomalies (CEMC-Auvergne), Department of Clinical Genetics, Centre de Référence des Maladies Rares, University Hospital of Clermont-Ferrand, Clermont-Ferrand, France.

Hanitra Randrianaivo (H)

Register of Congenital Malformations Isle of Reunion Island, CHU St Pierre, la Reunion, Reunion, France.

Judith Rankin (J)

National Congenital Anomaly and Rare Disease Registration Service, National Disease Registration Service, NHS Digital, Leeds, UK.
Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK.

Anke Rissmann (A)

Malformation Monitoring Centre Saxony-Anhalt, Medical Faculty Otto-von-Guericke University, Magdeburg, Germany.

Florence Rouget (F)

Brittany Registry of Congenital Anomalies, CHU Rennes, Univ Rennes, Inserm, EHESP, IRSET (Institut de Recherche en Santé, Environnement et Travail) - UMR_S 1085, Rennes, France.

Bruno Schaub (B)

French West Indies Registry, Registre des Malformations des Antilles (REMALAN), Maison de la Femme de la Mère et de l'Enfant, University Hospital of Martinique, Fort-de-France, France.

David Tucker (D)

Congenital Anomaly Register & Information Service for Wales (CARIS), Public Health Wales, Swansea, UK.

Diana Wellesley (D)

University Hospital Southampton, Faculty of Medicine and Wessex Clinical Genetics Service, Princess Anne Hospital, Southampton, UK.

Katarzyna Wiśniewska (K)

Epidemiology Unit, Department of Preventive Medicine, Poznan University of Medical Sciences, Poznan, Poland.

Lyubov Yevtushok (L)

OMNI-Net Ukraine Birth Defects Program and Rivne Regional Medical Diagnostic Center, Rivne, Ukraine.

Michele Santoro (M)

Unit of Epidemiology of Rare Diseases and Congenital Anomalies, Institute of Clinical Physiology, National Research Council, Pisa, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH